Claire Rychlewski is an Editor at Axios Pro. She specializes in medicine and healthcare, focusing on topics such as digital health, healthcare administration, and private healthcare, while also exploring themes in alternative investments and asset management. Claire's insights and expertise have been featured in Syncron, Axios, Industry Today Media, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Claire Rychlewski's coverage focuses on business, tech, health, healthcare & pharmaceutical industries. She appears to prioritize articles that include press releases and private sector announcements. Her article titles mostly revolve around mergers and acquisitions in the healthcare industry.
If you are looking to pitch to Claire Rychlewski, consider offering insights into recent M&A activities or significant developments within the healthcare, medtech, or telehealth sectors. Additionally, providing data-backed analysis or exclusive access to notable industry figures could be appealing to her given her frequent citations of data in her articles.
Given that there is no specified geographic focus for Claire’s coverage attributes suggest she takes a broad view of these industries with interest in international as well as domestic market movements and trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Helping patients take their medications as prescribed can improve health plan performance and financial results.
Efferon, a medical device company for pediatric sepsis, is raising a $20 million Series A round, CEO Dima Romashin tells Axios Pro exclusively.
HCAT will have to prove its remaining businesses can grow organically.
TPG and General Atlantic are among the PE firms circling Clinical Ink, a clinical trial tech business owned by GI Partners, Axios Pro has learned.
Pharma logistics has boomed with GLP-1s.
Trial recruitment is an expensive bottleneck for drug development.
By: Claire Rychlewski, Brock E.W. Turner
Wearables giants Oura and Whoop are pushing more deeply into women's health.
Kardigan, a clinical-stage cardiac disease drugmaker, raised about $400 million in its IPO.
Demand for pharmacovigilance is rising as drugmakers manage larger safety datasets, increasingly complex medicines and tighter regulatory scrutiny.
AbbVie said Monday it agreed to acquire Apogee Therapeutics for $10.9 billion in cash.
